Upgrade to SI Premium - Free Trial

Form D Kitov Pharma Ltd.

May 15, 2020 4:49 PM

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL
OMB Number:3235-0076
Expires:August 31, 2015
Estimated average burden
hours per response:4.00

1. Issuer's Identity

CIK (Filer ID Number)Previous Names
None
Entity Type
0001614744
Mainrom Line Logistics Ltd.
Kitov Pharmaceuticals Holdings Ltd.
Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
XOther (Specify)

Name of Issuer
Kitov Pharma Ltd.
Jurisdiction of Incorporation/Organization
ISRAEL
Year of Incorporation/Organization
XOver Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Kitov Pharma Ltd.
Street Address 1Street Address 2
ONE AZRIELI CENTERROUND BUILDING
CityState/Province/CountryZIP/PostalCodePhone Number of Issuer
TEL AVIVISRAEL670110197239333121

3. Related Persons

Last NameFirst NameMiddle Name
IsraelIsaac
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:XExecutive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Chief Executive Officer and Director of the Issuer
Last NameFirst NameMiddle Name
RowinskyEric
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:Executive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Independent Director and Chairman of the Board of Directors of the Issuer
Last NameFirst NameMiddle Name
RockSimcha
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:Executive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Director of the Issuer
Last NameFirst NameMiddle Name
SteinbergSteven
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:Executive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Independent Director of the Issuer
Last NameFirst NameMiddle Name
AgmonIdo
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:Executive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Independent Director of the Issuer
Last NameFirst NameMiddle Name
TzrorRan
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:Executive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Independent Director of the Issuer
Last NameFirst NameMiddle Name
Stern-RaffRevital
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:Executive OfficerXDirectorPromoter

Clarification of Response (if Necessary):

Independent Director of the Issuer
Last NameFirst NameMiddle Name
Ben-MenachemGil
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:XExecutive OfficerDirectorPromoter

Clarification of Response (if Necessary):

Vice President of Business Development of the Issuer
Last NameFirst NameMiddle Name
ReuveniHadas
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:XExecutive OfficerDirectorPromoter

Clarification of Response (if Necessary):

VP R&D of the Issuer
Last NameFirst NameMiddle Name
EfronGil
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:XExecutive OfficerDirectorPromoter

Clarification of Response (if Necessary):

Deputy CEO and Chief Financial Officer of the Issuer
Last NameFirst NameMiddle Name
LiangBertrand
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:XExecutive OfficerDirectorPromoter

Clarification of Response (if Necessary):

Chief Medical Officer of the Issuer
Last NameFirst NameMiddle Name
SchicklerMichael
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/PostalCode
Tel AvivISRAEL6701101
Relationship:XExecutive OfficerDirectorPromoter

Clarification of Response (if Necessary):

Head of Clinical Operations of the Issuer

4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Hedge Fund
Private Equity Fund
Venture Capital Fund
Other Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
XPharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other

5. Issuer Size

Revenue RangeORAggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
XDecline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
Rule 505
XRule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)

7. Type of Filing

XNew NoticeDate of First Sale2020-05-06 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
YesXNo

9. Type(s) of Securities Offered (select all that apply)

Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
XOption, Warrant or Other Right to Acquire Another Security Mineral Property Securities
XSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
YesXNo

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor$0USD

12. Sales Compensation

Recipient
Recipient CRD Number None
H.C. Wainwright & Co., LLC375
(Associated) Broker or DealerXNone
(Associated) Broker or Dealer CRD NumberXNone
NoneNone
Street Address 1Street Address 2
430 PARK AVENUE3RD FLOOR
CityState/Province/CountryZIP/Postal Code
NEW YORKNEW YORK10022
State(s) of Solicitation (select all that apply)
Check “All States” or check individual States
All States
Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount$10,000,001USD
or Indefinite
Total Amount Sold$10,000,001USD
Total Remaining to be Sold$0USD
or Indefinite

Clarification of Response (if Necessary):

Represents the aggregate amount received from investors in connection with Issuer's registered offering of ADSs and concurrent private placement of warrants, respectively, which were issued jointly to investors for a single purchase price.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
3

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions$700,000USD
XEstimate
Finders' Fees$0USD
Estimate

Clarification of Response (if Necessary):

Represents 7% commission of gross proceeds from investors for sale of ADSs in the registered offering and concurrent private placement of warrants. We also paid or reimbursed expenses of $62,900 and issued unregistered warrants to purchase up to 1,750,000

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

IssuerSignatureName of SignerTitleDate
Kitov Pharma Ltd./s/ Gil EfronGil EfronDeputy CEO and Chief Financial Officer2020-05-15

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


Categories

SEC Filings